The	0	3	O
modulation	4	14	O
of	15	17	O
platelet	18	26	B-Cell
and	27	30	O
endothelial	31	42	B-Cell
cell	43	47	I-Cell
adhesion	48	56	O
to	57	59	O
vascular	60	68	B-Multi-tissue_structure
graft	69	74	I-Multi-tissue_structure
materials	75	84	O
by	85	87	O
perlecan	88	96	B-Gene_or_gene_product
.	96	97	O

Controlled	99	109	O
neo	110	113	O
-	113	114	O
endothelialisation	114	132	O
is	133	135	O
critical	136	144	O
to	145	147	O
the	148	151	O
patency	152	159	O
of	160	162	O
small	163	168	O
diameter	169	177	O
vascular	178	186	B-Multi-tissue_structure
grafts	187	193	I-Multi-tissue_structure
.	193	194	O

Endothelialisation	195	213	O
and	214	217	O
platelet	218	226	B-Cell
adhesion	227	235	O
to	236	238	O
purified	239	247	O
endothelial	248	259	B-Cell
cell	260	264	I-Cell
-	264	265	O
derived	265	272	O
perlecan	273	281	B-Gene_or_gene_product
,	281	282	O
the	283	286	O
major	287	292	O
heparan	293	300	B-Gene_or_gene_product
sulfate	301	308	I-Gene_or_gene_product
(	309	310	I-Gene_or_gene_product
HS	310	312	I-Gene_or_gene_product
)	312	313	I-Gene_or_gene_product
proteoglycan	314	326	I-Gene_or_gene_product
in	327	329	O
basement	330	338	B-Cellular_component
membranes	339	348	I-Cellular_component
,	348	349	O
were	350	354	O
investigated	355	367	O
using	368	373	O
in	374	376	O
vivo	377	381	O
and	382	385	O
in	386	388	O
vitro	389	394	O
assays	395	401	O
.	401	402	O

Expanded	403	411	O
polytetrafluoroethylene	412	435	B-Drug_or_compound
(	436	437	O
ePTFE	437	442	B-Drug_or_compound
)	442	443	O
vascular	444	452	B-Multi-tissue_structure
grafts	453	459	I-Multi-tissue_structure
were	460	464	O
coated	465	471	O
with	472	476	O
perlecan	477	485	B-Gene_or_gene_product
and	486	489	O
tested	490	496	O
in	497	499	O
an	500	502	O
ovine	503	508	O
carotid	509	516	O
interposition	517	530	O
model	531	536	O
for	537	540	O
a	541	542	O
period	543	549	O
of	550	552	O
6	553	554	O
weeks	555	560	O
and	561	564	O
assessed	565	573	O
using	574	579	O
light	580	585	O
and	586	589	O
scanning	590	598	O
microscopy	599	609	O
.	609	610	O

Enhanced	611	619	O
endothelial	620	631	B-Cell
cell	632	636	I-Cell
growth	637	643	O
and	644	647	O
reduced	648	655	O
platelet	656	664	B-Cell
adhesion	665	673	O
were	674	678	O
observed	679	687	O
on	688	690	O
the	691	694	O
perlecan	695	703	B-Gene_or_gene_product
coated	704	710	O
grafts	711	717	B-Multi-tissue_structure
when	718	722	O
compared	723	731	O
to	732	734	O
uncoated	735	743	O
controls	744	752	O
implanted	753	762	O
in	763	765	O
the	766	769	O
same	770	774	O
sheep	775	780	B-Organism
(	781	782	O
n	782	783	O
=	783	784	O
5	784	785	O
)	785	786	O
.	786	787	O

Perlecan	788	796	B-Gene_or_gene_product
was	797	800	O
also	801	805	O
found	806	811	O
to	812	814	O
stimulate	815	824	O
endothelial	825	836	B-Cell
cell	837	841	I-Cell
proliferation	842	855	O
in	856	858	O
vitro	859	864	O
over	865	869	O
a	870	871	O
period	872	878	O
of	879	881	O
6	882	883	O
days	884	888	O
in	889	891	O
the	892	895	O
presence	896	904	O
of	905	907	O
plasma	908	914	B-Organism_substance
proteins	915	923	O
and	924	927	O
fibroblastic	928	940	B-Gene_or_gene_product
growth	941	947	I-Gene_or_gene_product
factor	948	954	I-Gene_or_gene_product
2	955	956	I-Gene_or_gene_product
(	957	958	O
FGF	958	961	B-Gene_or_gene_product
-	961	962	I-Gene_or_gene_product
2	962	963	I-Gene_or_gene_product
)	963	964	O
,	964	965	O
however	966	973	O
in	974	976	O
the	977	980	O
absence	981	988	O
of	989	991	O
FGF	992	995	B-Gene_or_gene_product
-	995	996	I-Gene_or_gene_product
2	996	997	I-Gene_or_gene_product
endothelial	998	1009	B-Cell
cell	1010	1014	I-Cell
growth	1015	1021	O
could	1022	1027	O
not	1028	1031	O
be	1032	1034	O
maintained	1035	1045	O
during	1046	1052	O
this	1053	1057	O
period	1058	1064	O
.	1064	1065	O

Perlecan	1066	1074	B-Gene_or_gene_product
was	1075	1078	O
found	1079	1084	O
to	1085	1087	O
be	1088	1090	O
anti	1091	1095	O
-	1095	1096	O
adhesive	1096	1104	O
for	1105	1108	O
platelets	1109	1118	B-Cell
,	1118	1119	O
however	1120	1127	O
after	1128	1133	O
removal	1134	1141	O
of	1142	1144	O
the	1145	1148	O
HS	1149	1151	O
chains	1152	1158	O
attached	1159	1167	O
to	1168	1170	O
perlecan	1171	1179	B-Gene_or_gene_product
,	1179	1180	O
platelet	1181	1189	B-Cell
adhesion	1190	1198	O
and	1199	1202	O
aggregation	1203	1214	O
were	1215	1219	O
supported	1220	1229	O
.	1229	1230	O

These	1231	1236	O
results	1237	1244	O
suggest	1245	1252	O
a	1253	1254	O
role	1255	1259	O
for	1260	1263	O
HS	1264	1266	B-Protein_domain_or_region
chains	1267	1273	I-Protein_domain_or_region
of	1274	1276	O
perlecan	1277	1285	B-Gene_or_gene_product
in	1286	1288	O
improving	1289	1298	O
graft	1299	1304	B-Multi-tissue_structure
patency	1305	1312	O
by	1313	1315	O
selectively	1316	1327	O
promoting	1328	1337	O
endothelial	1338	1349	B-Cell
cell	1350	1354	I-Cell
proliferation	1355	1368	O
while	1369	1374	O
modulating	1375	1385	O
platelet	1386	1394	B-Cell
adhesion	1395	1403	O
.	1403	1404	O

